Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + miconazole is a non-standard, compounded topical combination of two small molecule drugs—ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), and miconazole, an azole antifungal. Ibuprofen acts as a non-selective cyclooxygenase (COX) inhibitor to reduce pain, inflammation, and fever[4]. Miconazole inhibits fungal CYP450 14α-lanosterol demethylase activity to disrupt ergosterol synthesis in fungal cell membranes, leading to broad-spectrum antifungal effects[1]. This combination has been used in compounded preparations for topical application (such as ointments for nipple pain during breastfeeding) to provide both anti-inflammatory and antifungal benefits[8]. There is also evidence that NSAIDs like ibuprofen may have direct antifungal activity and can act synergistically with azoles against Candida species when applied topically[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + miconazole.